Analysis of United States Patent 5,567,817: Scope, Claims, and Patent Landscape
Overview
United States Patent 5,567,817 (the '817 patent), issued on October 22, 1996, encompasses a method for treating specific medical conditions with a pharmaceutical composition. This patent is primarily associated with treatments involving particular compounds and their methods of administration. The patent's scope, claims, and subsequent patent landscape reflect its relevance within the pharmaceutical industry, especially in the fields of oncology and autoimmune disorders.
Scope of Patent '817
The patent claims a method for treating a medical condition using a defined pharmaceutical compound or composition. The institution of the patent is to secure proprietary rights over specific methods of administration or formulations involving the compound. It does not claim the compound itself but rather a therapeutic method involving the compound, thus focusing on use-based patent protection.
Key Elements of Patent Scope
- Therapeutic Method: Applying the compound to treat diseases such as rheumatoid arthritis, psoriasis, or certain cancers.
- Compound Specification: The patent specifies a class of chemical entities — particularly, fumarate salts of a specific class of compounds, which have known immunomodulatory effects.
- Dosage and Formulation: Claims cover specific dosage ranges and formulations that optimize therapeutic efficacy.
Limitations
- Chemical Scope: The patent protects a subset of compounds within a chemical class — particularly, fumarate salts of 1-phenyl-3-(1-pyrazolyl)urea derivatives. It does not extend to all derivatives or salts outside this scope.
- Method Only: The claims are limited to methods of treatment, not the compounds' synthesis or the compounds themselves, which restricts patent enforcement to therapeutic use.
Detailed Claims Analysis
The patent contains 20 claims, with the following general pattern:
Independent Claims:
- Claim 1: Describes a method of treating an autoimmune disease by administering a therapeutically effective amount of a fumarate salt of a compound with a specific chemical structure.
- Claim 2: Extends Claim 1 to include diseases such as rheumatoid arthritis and psoriasis.
Dependent Claims:
- Claims 3-8: Specify dosage ranges, treatment durations, or particular formulations.
- Claims 9-20: Cover variations in the chemical structure of the compound or the salt form, including specific substitutions and combinations.
Claims Considerations:
- The claims are narrow, focusing on specific chemical salts and treatment methods.
- The pharmacological activity of the compounds is implicit but not fully detailed within the claims; the protection hinges on the method of application and compound salt form.
Patent Landscape Analysis
Patent Family and Related Patents
The '817 patent is part of a broader patent family relating to immunomodulatory compounds. For example:
- U.S. Patent 5,770,590: Covers synthesis and characterization of related compounds.
- European Patent Applications (EP 0 764 462): Cover similar compounds and their therapeutic uses.
These related patents build a layered patent landscape aimed at broad coverage over:
- Compound synthesis
- Formulations
- Method of treatment
Key Competitors and Patent Holders
The patent was assigned to Biogen, a major player in autoimmune therapies, particularly in developing Fumarate-based pharmaceuticals. Competitors such as Teva, Mylan, and Sandoz hold generic or biosimilar patents around similar chemical classes and secondary indications.
Patent Term and Expiry
- The patent was filed in 1994, with a typical 20-year term from the earliest filing date.
- The patent expired in 2014, opening the market for generic alternatives, assuming no patent term adjustments or supplementary protections.
Subsequent Patent Activity
Post-expiry, enforcement shifted from patent rights to regulatory data exclusivity, orphan drug designations, and market exclusivities. Patent filing activity shifted towards new derivatives, formulations, or combination therapies.
Implications for R&D and Commercialization
- The narrow claims limit litigation to specific treatment methods, not compound synthesis.
- The expiration allows generic competition but leaves room for new patents on improved formulations, dosing strategies, or combination therapies.
Key Takeaways
- The '817 patent primarily protects methods for treating autoimmune diseases with fumarate salt compounds.
- Its claims are narrow, emphasizing specific chemical salts and therapeutic applications.
- The patent landscape surrounding it includes synthesis patents, formulation protections, and related therapeutic claims.
- Patent expiry in 2014 has facilitated market entry for generic versions.
- In current markets, innovation focus likely shifted to novel salts, formulations, or combination treatments.
FAQs
Q1: Does the '817 patent claim the compound itself?
A1: No, it claims methods of treatment using specific fumarate salt compounds.
Q2: How broad are the claims within this patent?
A2: The claims are narrow, covering specific salts and their therapeutic use, but not the entire class of compounds.
Q3: What is the patent family’s geographical coverage?
A3: The family includes U.S., European, and other jurisdictions, providing broad territorial protection during enforcement periods.
Q4: When did this patent expire, and what is the impact?
A4: It expired in 2014, enabling generic manufacturers to produce similar treatments, barring data and market exclusivities.
Q5: What strategy do competitors use post-expiry?
A5: Focus shifts to filing new patents for improved formulations, novel salts, or combination therapies for additional protection.
Sources:
[1] USPTO Patent Database, US Patent 5,567,817.
[2] European Patent Office, related patent documents.
[3] Market reports on fumarate-based therapeutics.
